A Systematic Approach to Evaluate Herb-Drug Interaction Mechanisms: Investigation of Milk Thistle Extracts and Eight Isolated Constituents as CYP3A Inhibitors

Scott J. Brantley, Tyler N. Graf, Nicholas H. Oberlies, and Mary F. Paine

Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (S.J.B., M.F.P.); and Department of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro, North Carolina (T.N.G., N.H.O.)

Received April 18, 2012; accepted June 25, 2013

ABSTRACT

Despite increasing recognition of potential untoward interactions between herbal products and conventional medications, a standard system for prospective assessment of these interactions remains elusive. This information gap was addressed by evaluating the drug interaction liability of the model herbal product milk thistle (Silybum marianum) with the CYP3A probe substrate midazolam. The inhibitory effects of commercially available milk thistle extracts and isolated constituents on midazolam 1′-hydroxylation were screened using human liver and intestinal microsomes. Relative to vehicle, the extract silymarin and constituents silybin A, isosilybin A, isosilybin B, and silychristin at 100 μM demonstrated >50% inhibition of CYP3A activity with at least one microsomal preparation, prompting IC_{50} determination. The IC_{50}s for isosilybin B and silychristin were ~60 and 90 μM, respectively, whereas those for the remaining constituents were >100 μM. Extracts and constituents that contained the 1,4-dioxane moiety demonstrated a >1.5-fold shift in IC_{50} when tested as potential mechanism-based inhibitors. The semipurified extract, silibinin, and the two associated constituents (silybin A and silybin B) demonstrated mechanism-based inhibition of recombinant CYP3A4 (K_{p} ~100 μM; k_{react} ~0.20 min^{-1}) but not microsomal CYP3A activity. The maximum predicted increases in midazolam area under the curve using the static mechanistic equation and recombinant CYP3A4 data were 1.75-fold, which may necessitate clinical assessment. Evaluation of the interaction liability of single herbal product constituents, in addition to commercially available extracts, will enable elucidation of mechanisms underlying potential clinically significant herb-drug interactions. Application of this framework to other herbal products would permit predictions of herb-drug interactions and assist in prioritizing clinical evaluation.

Introduction

An estimated 20% of adults in the United States acknowledge taking herbal products (Bent, 2008), with nearly 70% failing to inform their health care provider (Gardiner et al., 2006; Kennedy et al., 2008). An herbal product that inhibits one or more drug-metabolizing enzymes can perpetrate untoward interactions with conventional medications (Hu et al., 2005; Izzo and Ernst, 2009; Gurley et al., 2012). Prominent among these enzymes are the cytochromes P450 (P450s). Inhibition of P450 activity by constituents of the herbal product can reduce “victim” drug clearance, leading to higher systemic drug concentrations and potential adverse effects and toxicity. Dietary substances, including herbal products, are not regulated in the same manner as drugs. Consequently, herb-drug interaction liability is not evaluated routinely prior to marketing. This information gap prevents both clinicians and consumers from making informed decisions about the risk of adding herbal products to pharmacotherapeutic regimens.

Despite increasing recognition of potential untoward herb-drug interactions, a standard system for prospective assessment of the drug interaction liability of herbal products remains elusive. In addition to inconsistent experimental methods, variability in phytochemical content further confounds interaction evaluations (Gurley, 2012). As such, knowledge of mechanisms underlying these interactions is scarce. One approach to developing a system to assess herb-drug interaction potential is to examine individual constituents from a well-characterized herbal product using traditional drug-drug interaction predictive tools. Milk thistle is a top-10-selling herbal product in the United States (Blumenthal et al., 2012) used predominately to self-treat hepatic disorders, particularly hepatitis C (Kroll et al., 2007; Post-White et al., 2007; Seeff et al., 2008). Milk thistle represents an ideal...
model herbal product due to the following key properties: high sales numbers ($12.8 million in 2011) indicate that a large number of consumers are at risk for milk thistle–drug interactions (Blumenthal et al., 2012); individual constituents have been identified, isolated, and scaled up to quantities sufficient for in vitro drug-drug interaction evaluation (Kim et al., 2003; Graf et al., 2007; Monti et al., 2010; Sy-Cordero et al., 2012); and in vitro–in vivo extrapolation has been inconsistent (Beckmann-Knopp et al., 2000; Zuber et al., 2002; Gurley et al., 2004, 2006; Han et al., 2009).

Commercial preparations of milk thistle [Silybum marianum (L.) Gaertn.] include the crude extract silymarin, consisting of at least seven flavonolignans (Fig. 1), the flavonoid taxifolin, and fatty acids; and the semipurified extract silibinin, consisting of the most prevalent flavonolignans (silybin A and silybin B). The relative composition of milk thistle constituents varies substantially between and among preparations (Davis-Searles et al., 2005; Wen et al., 2008). These extracts have been shown to inhibit the activity of several P450s in vitro, both reversibly (e.g., CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A) (Beckmann-Knopp et al., 2000; Zuber et al., 2002; Etheridge et al., 2007; Doehmer et al., 2008; Brantley et al., 2010) and irreversibly (e.g., CYP2C9 and CYP3A4) (Sridar et al., 2004). However, these in vitro observations generally have not manifested clinically. For example, two healthy volunteer studies demonstrated no interaction between the CYP3A probe substrate midazolam and one silymarin product (Gurley et al., 2004, 2006), whereas another study demonstrated a different silymarin product to significantly increase the systemic exposure to the CYP2C9/3A substrate losartan (Han et al., 2009). This discrepancy may be attributed to large variation in relative composition between herbal products. Rigorous characterization of P450 inhibition properties of individual constituents, as well as the commercial extracts, may assist explanation of these in vitro–in vivo disconnects (Paine and Oberlies, 2007; Won et al., 2012).

CYP3A metabolizes >30% of clinically used drugs (Zanger and Schwab, 2013) and is expressed in both the intestine and liver (Thummel et al., 1996). Following oral administration of milk thistle, intestinal CYP3A likely will be exposed to higher concentrations of the constituents compared with hepatic CYP3A. This difference was demonstrated by the nearly 60-fold-higher mean (± S.D.) concentration in intestinal relative to hepatic tissue in cancer patients administered 1.4 g/day silibinin (140 ± 170 versus 2.5 ± 2.4 μM) (Hoh et al., 2006). Such high intestinal concentrations could markedly reduce the intestinal first-pass metabolism of susceptible CYP3A substrates, thereby

![Fig. 1. Structures of flavonolignans and flavonoid (taxifolin) from milk thistle.](https://example.com)
increasing systemic drug exposure. Using milk thistle as a model herbal product, the objectives of this study were to 1) assess interaction liability of individual constituents toward CYP3A activity, 2) prioritize constituents for further evaluation, and 3) develop a framework to elucidate mechanisms underlying herb-drug interactions. Such mechanistic insight ultimately may assist clinicians and consumers to gauge the impact of adding herbal products to pharmacotherapeutic regimens.

Materials and Methods

Chemicals and Reagents

Human liver (pooled from 50 donors, mixed gender) and intestinal (pooled from 18 donors, mixed gender) microsomes (HLMs and HMs, respectively) were purchased from Xenotech, LLC (Lenexa, KS). Baculovirus insect cell–expressed CYP3A4 (rCYP3A4), supplemented with cDNA-expressed reductase and cytochrome b5, was purchased from BD Biosciences (San Jose, CA). Midazolam, 1′-hydroxymidazolam, alprazolam, silybinin, ketoconazole, NADPH, glutathione, superoxide dismutase, catalase, 5,5-dimethyl-1-pyrroline N-oxide, acetonitrile, dimethylsulfoxide (DMSO), high-performance liquid chromatography (HPLC)-grade water, methanol, ammonium acetate, and 1-propanol were purchased from Sigma-Aldrich (St. Louis, MO). 6′,7′-Dihydroxyberganotinin (DHB) was purchased from Cayman Chemical (Ann Arbor, MI). Silymarin was obtained from Euromed S.A. (Barcelona, Spain). This product has been shown to consist of 16% silybin A, 24% silybin B, 6.4% isosilybin A, 4.4% isosilybin B, 17% silydianin, 12% silychristin, 2.2% isosilychristin, and 1.6% taxifolin; the remainder consists of uncharacterized polyphenols and aliphatic fatty acids (Davis-Searles et al., 2005). Silybin A, silybin B, isosilybin A, isosilybin B, silychristin, isosilychristin, silydianin, and taxifolin were purified as described previously (Graf et al., 2007); all milk thistle constituents were >97% pure as determined by HPLC.

Evaluation of the Stability of Individual Milk Thistle Constituents

Stability in Potassium Phosphate Buffer. Each constituent was dissolved in DMSO to yield a 100 mM solution. Each solution was diluted in potassium phosphate buffer (0.1 M, pH 7.4), supplemented with MgCl2 (3.3 mM) to yield a final concentration of 100 μM. Solutions were placed immediately into a heated (37°C) autosampler, and aliquots (0.3 μl) were collected serially from 0–1440 minutes and analyzed via UPLC-UV (described below).

Metabolic Lability of Selected Constituents. Silybin A, silybin B, isosilybin A, and isosilybin B were added to potassium phosphate buffer as described above with the addition of HLMs (0.05 mg/ml). Incubation mixtures were placed on a dry heat block and equilibrated for 5 minutes. Reactions were initiated with the addition of NADPH to yield a final concentration of 1 mM. Aliquots (100 μl) were removed and diluted 5-fold into a secondary incubation mixture containing midazolam (1 mM) and potassium phosphate buffer were equilibrated at 37°C for 5 minutes before initiating reactions with NADPH (1 mM). Control reactions were identical except NADPH was replaced with potassium phosphate buffer. After 15 minutes, an aliquot (40 μl) was removed and diluted 5-fold into a secondary incubation mixture containing midazolam (4 μM) and potassium phosphate buffer were equilibrated at 37°C for 5 minutes before initiating reactions with NADPH (1 mM). Control reactions were identical except NADPH was replaced with potassium phosphate buffer. After 15 minutes, an aliquot (40 μl) was removed and diluted 5-fold into a secondary incubation mixture containing midazolam (4 μM) and NADPH (1 mM). After 2 (HLMs) or 4 (HMs) minutes, the secondary reactions were terminated and processed as described above. Individual constituents demonstrating >1.5-fold shift in IC50 were selected for further evaluation.

Effect of Nucleophilic Trapping Agents and Reactive Oxygen Species Scavengers on CYP3A Inactivation in HLMs. Primary mixtures consisted of HLMs (0.25 mg/ml), silybin A (0, 30, or 100 μM), potassium phosphate buffer, and trapping agent [5,5-dimethyl-1-pyrroline N-oxide (1 mM), superoxide dismutase (1,000 U/ml), glutathione (2 mM), or catalase (5,000 U/ml)]. The mixtures were equilibrated at 37°C for 5 minutes before initiating reactions with NADPH (1 mM). Control reactions were identical except NADPH was replaced with potassium phosphate buffer. After 15 minutes, an aliquot (40 μl) was removed and diluted 5-fold into a secondary reaction mixture containing midazolam (4 μM) and potassium phosphate buffer were equilibrated at 37°C for 5 minutes before initiating reactions with NADPH (1 mM). After 2 (HLMs) or 4 (HMs) minutes, the secondary reactions were terminated and processed as described above. Individual constituents demonstrating a >1.5-fold shift in IC50 were selected for further evaluation.

Determination of Mechanism-Based Inhibition Kinetics. Time- and concentration-dependent inhibition of CYP3A4 was assessed as described previously (Paine et al., 2004). Briefly, primary incubation mixtures consisting of HLMs, HMs (2.5 mg/ml), or rCYP3A4 (0.2 mM/ml), milk thistle constituent/extract (0–200 μM), and potassium phosphate buffer were equilibrated at 37°C for 5 minutes before initiating the primary reactions with NADPH. As a positive control for mechanism-based inhibition (MBI), incubation mixtures contained DHB (5 μM) in place of milk thistle constituent/extract (Paine et al., 2004). At designated times (0–15 minutes), an aliquot (4 μl) was removed and diluted 50-fold into a secondary reaction mixture containing midazolam (8 μM) and NADPH (1 mM). The secondary reactions were terminated and processed as described for the reversible inhibition experiments.

Data Analysis

Determination of Apparent IC50. The apparent IC50 of milk thistle constituent/extract was recovered according to previously published methods (Brantley et al., 2010). Initial estimates of IC50 were determined by visual inspection of the velocity of 1′-hydroxymidazolam formation versus the natural logarithm of milk thistle constituent/extract concentration data. Final parameter estimates were recovered by fitting eq. 1 or 2 to untransformed data using WinNonlin (version 5.3; Pharsight, Mountain View, CA):
where $v$ denotes the velocity of 1'-hydroxymidazolam formation, $v_0$ denotes the initial velocity of 1'-hydroxymidazolam formation, $I$ denotes the concentration of milk thistle constituent/extract, and $h$ denotes the Hill coefficient. The best-fit equation was assessed from visual inspection of the observed versus predicted data, randomness of the residuals, Akaike information criteria, and S.E.’s of the parameter estimates.

**Determination of $K_I$ and $k_{\text{inact}}$.** MBI parameters were recovered according to previously published methods (Paine et al., 2004; Obach et al., 2007). Briefly, the natural logarithm of the percentage of CYP3A activity remaining was plotted as a function of primary reaction time. The apparent inactivation rate constant ($k_{\text{inact,app}}$) associated with each inhibitor concentration was determined from the slope of the initial mono-exponential decline in activity. Initial estimates of $K_I$ and $k_{\text{inact}}$ were obtained from a Kitz-Wilson plot. Final parameter estimates were obtained by nonlinear least-squares regression using eq. 3:

$$k_{\text{inact,app}} = k_{\text{zero}} + k_{\text{inact}}^*f$$  

where $k_{\text{zero}}$ denotes the rate of CYP3A inactivation in the absence of inhibitor. The efficiency of inactivation was calculated as the ratio of $k_{\text{inact}}$ to $K_I$.

**Milk Thistle–Midazolam Drug Interaction Prediction.** The interaction between milk thistle constituents and midazolam was predicted using the intestinal portion of the static mechanistic MBI equation detailed previously (Obach et al., 2007; US FDA, 2012):

$$AUC_i = \frac{1}{F_g + \left(1 - F_g\right)^*\left(\frac{1}{1 + \left(\frac{k_{\text{inact}}*I_g}{k_{\text{deg}}*(I_g + K_I)}\right)}\right)}$$  

where $AUC_i/AUC$ denotes the predicted ratio of in vivo exposure of a victim drug, $I_g$ denotes the inhibitor concentration in the enterocyte (140 μM) after a silibinin dose of 1.4 g (Hoh et al., 2006), $k_{\text{deg}}$ denotes the rate of intestinal CYP3A4 degradation (0.00481 min⁻¹) (Obach et al., 2007), and $F_g$ denotes the fraction of the dose of midazolam escaping first-pass extraction in the intestine (0.57) (Paine et al., 1996).

**Statistical Analysis**

Data are presented as means ± S.D.’s of triplicate determinations unless indicated otherwise. Enzyme kinetic parameters are presented as the estimates ± S.E.’s. All statistical comparisons were made according to previously published methods (Brantley et al., 2010). In brief, concentration-dependent inhibition of single constituents/extracts was evaluated by a one-way analysis of variance; post hoc comparisons were made using Tukey’s test when an overall significance resulted. Statistical differences between calculated IC₅₀ values were evaluated by a Student’s t test of two independent samples. A P < 0.05 was considered significant for all statistical tests.

**Results**

**Selected Milk Thistle Constituents Are Metabolically Stable in HLMs for up to 15 Minutes**

All tested constituents were stable (>95% remaining) for 1 hour at 37°C in potassium phosphate buffer (data not shown). Metabolic stability experiments determined the optimal primary incubation time such that inhibitor depletion would be ≤20%. All constituents at 10 μM demonstrated ≥50% oxidative depletion by 60 minutes (Fig. 2). Isosilybin A was the least stable, showing 40% depletion by 10 minutes, whereas the remaining constituents were depleted by <10%. At 100 μM, silybin A was slightly more stable than the other constituents (~40% versus 50% depletion by 60 minutes). Isosilybin A at 100 μM was again the least stable, showing 30% depletion by 10 minutes, whereas the remaining constituents were depleted by <10%. Based on these observations, the primary incubation time of the IC₅₀ shift and MBI experiments involving selected constituents, with the exception of isosilybin A, was limited to 15 minutes.

**Milk Thistle Constituents Differentially Inhibit CYP3A-Mediated Midazolam 1'-Hydroxylation**

**Initial Testing.** All flavonolignans and the two extracts (silibinin and silymarin) inhibited midazolam 1'-hydroxylation in a concentration-dependent manner (10 versus 100 μM) in HLMs (Fig. 3A) and, with the exception of isosilychristin, in HIMs (Fig. 3B). The sole flavonoid, taxifolin, showed no concentration-dependent inhibition with either preparation. Only silybin B (HLMs), silychristin (HIMs), and silydianin (HIMs) showed concentration-dependent inhibition from 1 to 10 μM (data not shown). With HLMs, silybin A at 100 μM was the most potent, followed by silymarin, isosilybin B, and isosilybin A (Fig. 3A); with HIMs, silymarin at 100 μM was the most potent, followed by isosilybin A, isosilybin B, and silychristin (Fig. 3B). Ketoconazole inhibited CYP3A activity in both microsomal preparations by at least 95% (data not shown). Based on >50% inhibition at 100 μM in at least one microsomal preparation, silybin A, isosilybin A, isosilybin B, and silychristin were selected for IC₅₀ determination. Additionally, based on the high concentrations (>140 μM) observed in enterocytes following silibinin administration to human subjects (Hoh et al., 2006), silybin B was selected for further evaluation.

**Reversible Inhibition.** With both HLMs and HIMs, isosilybin B was the most potent constituent, followed by silychristin, silybin B, and silybin A (Table 1). Because isosilybin A was not soluble at concentrations of >100 μM, a complete IC₅₀ curve could not be recovered.

**IC₅₀ Shift.** The IC₅₀ for silybin A, silybin B, and silybinin was 73%–98% lower in the presence compared with the absence of NADPH in the primary incubation (Table 2). rCYP3A4 was more sensitive to
inhibition than HLMs and HIMs (Fig. 4; Table 2). The IC50 for silychristin did not decrease with either HLMs or HIMs (Table 2), precluding further evaluation of this constituent. Reactive species scavengers did not ameliorate the NADPH-dependent increase in potency of silybin A toward CYP3A activity (Fig. 5).

**Silybin A, Silybin B, and Silibinin Demonstrate MBI of rCYP3A4 But Not Microsomal CYP3A Activity**

MBI of CYP3A activity by silybin A, silybin B, and silibinin was evaluated to derive relevant kinetic parameters. No tested constituent or extract demonstrated time- and concentration-dependent inhibition of CYP3A activity with either HLMs or HIMs (data not shown). Unlike with microsomes, rCYP3A4 demonstrated both time- and concentration-dependent inhibition (Fig. 6). Because the rate of rCYP3A4 inactivation for silybin B at 200 μM deviated from linearity (Fig. 6B), these data were excluded from further analysis. The kinetics were similar between silybin A and silybin B; the kinetics of the 1:1 mixture of silybin A and silybin B (silibinin) were similar to those recovered for the single constituents (Table 3). Using the rCYP3A4 inactivation parameters recovered for silibinin and assuming the enterocyte concentration of silibinin approximates that measured in intestinal tissue (Hoh et al., 2006), a 1.75-fold increase in midazolam area under the curve was predicted by the static mechanistic equation (Obach et al., 2007; US FDA, 2012).

**Discussion**

Herb-drug interactions are a growing concern in clinical practice as consumers turn increasingly to herbal products as a means to self-treat various conditions. Despite increasing recognition of these potential untoward interactions, a standard system for prospective assessment of the drug interaction liability of herbal products remains elusive. Milk thistle...
thistle was selected as a model herbal product based on market share, well-characterized nature, and clinical relevance. Milk thistle extracts have been reported to inhibit P450 activity in vitro (Beckmann-Knopp et al., 2000; Zuber et al., 2002; Doehmer et al., 2008); however, clinical interaction liability has been inconsistent, particularly with CYP3A-mediated interactions (Gurley et al., 2004, 2006; Han et al., 2000; Zuber et al., 2002; Doehmer et al., 2008); however, except for silychristin, all tested constituents and both extracts differentially inhibited CYP3A-mediated midazolam 1'-hydroxylation (Fig. 3). The crude extract silymarin was consistently one of the most potent inhibitors of CYP3A activity in microsomal preparations. Among single constituents, the relatively less abundant isosilybin A and isosilybin B (Davis-Searles et al., 2005; Wen et al., 2008) were two of the more potent inhibitors in both HLMs and HIMs (Fig. 3). Inhibitory kinetic parameters were recovered for isosilybin B, whereas metabolic lability (Fig. 2) and insolubility above 100 μM precluded recovery of these parameters for isosilybin A. Inhibition of midazolam 1'-hydroxylation in HLMs by silymarin at 100 μM (47%) was comparable to that by a different silymarin product at approximately 50 μM (43%) in a previous study (Etheridge et al., 2007). With microsomal preparations, silybinin was a slightly more potent inhibitor of both nifedipine dehydrogenation (IC50, 27–60 μM) (Zuber et al., 2002) and testosterone 6β-hydroxylation (IC50, 50 μM) (Jancova et al., 2007) compared with midazolam 1'-hydroxylation (IC50, 67–120 μM). Although these comparisons of IC50 values have inherent limitations, the apparent substrate-dependent inhibition is consistent with multiple CYP3A4 substrate-binding domains (Schrag and Wienkers, 2001; Galetin et al., 2003). Because midazolam was the only substrate tested in the current work, the reversible inhibition kinetics of individual constituents may not correlate with other CYP3A subclasses. In addition, the extent of inhibition by silymarin at 100 μM was greater than expected assuming additive inhibition by flavonolignans in aggregate (Fig. 3); suggesting the potential for synergistic inhibition of CYP3A by milk thistle flavonolignans. Further evaluation is needed to confirm this putative synergism.

Except for silychristin, all tested constituents and both extracts demonstrated potential MBI of CYP3A activity with HLMs, HIMs, and rCYP3A4 (Table 2), as evidenced by a >1.5-fold shift in IC50 (Berry and Zhao, 2008). However, the kinetic parameters associated with MBI could only be recovered using rCYP3A4. The Ki for silybinin in the current work (110 μM) was within, whereas the k_{inact} (0.20 min⁻¹) was roughly 3 times faster than, corresponding parameters reported using the CYP3A substrates 7-benzoyloxy-4-(trifluoromethyl) coumarin (32 μM and 0.06 min⁻¹) and testosterone (132 μM and 0.08 min⁻¹) (Sridar et al., 2004). The difference in k_{inact} may reflect different enzyme sources (recombinant versus reconstituted CYP3A4). Loss of rCYP3A4 activity was rapid, occurring within the 2- to 4-minute incubation times for the reversible inhibition experiments. As such, some MBIs would be expected under these
Isolated enzyme systems are believed to be enzyme inactivation through substrate protection (Silverman, 1995). Unlike with rCYP3A4 (current work) and reconstituted CYP3A4 (Sridar et al., 2004), MBI was not evident with either microsomal preparation. P450-mediated metabolism can generate superoxide and/or hydrogen peroxide, potentially leading to enzyme autoinactivation (Kalgutkar et al., 2007). Isolated enzyme systems are believed to be more sensitive to reactive oxygen species, manifesting as MBI-like behavior; however, inclusion of reactive species scavengers would abrogate this process (Kalgutkar et al., 2007). The likely presence of CYP3A5 in the microsomal preparations also may have compensated for the loss of CYP3A4 activity. Unlike the IC$_{50}$ shift experiment, saturating substrate concentrations were used for the MBI experiment, allowing potential compensation by CYP3A5 if this enzyme is less susceptible to MBI (McConn et al., 2004).

The major oxidative metabolite of silybin is reported to be an O-demethylated product produced by CYP2C8 and CYP3A4 (Jancova et al., 2007). Further oxidation of the resulting catechol could create a reactive 1,2-benzoquinone moiety. However, MBI by this mode was unlikely, as MBI was not observed with compounds containing either the catechol (taxifolin) (data not shown) or the 2-methoxyphenol (silychristin) moiety (Fig. 1; Table 2). The only constituents that tested positive for MBI contained a 1,4-dioxane moiety (Fig. 1). Oxidation of this region may create reactive oxygen species capable of inactivating CYP3A4. Since activity loss was not abrogated by the trapping agents, the inactivating species exerted their effect before leaving the CYP3A4 active site. If this proposed mode of MBI is verified, this chemical moiety may be considered an addition to the list of structural alerts (Kalgutkar et al., 2007).

Following typical “doses” (~600 mg/day) of milk thistle preparations, individual constituents achieve relatively low peak systemic concentrations (C$_{max}$ <1 μM) and are cleared rapidly from the systemic circulation (half-life, <4 hours) (Wen et al., 2008). Accordingly, the interaction potential of milk thistle due to reversible inhibition likely is limited to inhibition of first-pass clearance of sensitive substrates. The clinical interaction potential for mechanism-based inhibitors is higher than that for reversible inhibitors, because restoration of P450 activity is dependent on de novo protein synthesis rather than removal of the perpetrator compound(s) (Watanabe et al., 2007). For example, MBI has been hypothesized as the only means by which fruit juices can elicit clinically significant interactions with CYP3A substrates (Hanley et al., 2012). Whereas the maximum rates of rCYP3A4 inactivation by silybin A and silybin B were roughly half those reported for a major mechanism-based inhibitor in grapefruit juice, DHB (−0.20 versus 0.41 min$^{-1}$) (Paine et al., 2004), the K$_{h}$ for silybin A and silybin B were ~100 times greater than those for DHB (~100 versus 1.1 μM). Thus, at equivalent exposures, DHB will inactivate CYP3A4 much more efficiently than the milk thistle constituents (370 versus ~2 μl/min/pmol).

The high K$_{h}$ and low systemic exposure of silybin A and silybin B following milk thistle administration indicate a low risk for an interaction between milk thistle at typical doses and midazolam. The much higher colorectal tissue concentrations of silybin compared with peripheral blood concentrations (140 ± 170 versus 3.0 ± 2.3 μM) following administration of 1.4 g/day to cancer patients (Hoh et al., 2006) further indicate that any clinically relevant MBI of CYP3A likely will be limited to the intestine. Enterocyte concentrations of silybin this high would be expected to produce a 1.75-fold increase in systemic midazolam exposure based on the mechanistic static MBI equation (Obach et al., 2007; US FDA, 2012). Although the extent of MBI was not consistent between different enzyme preparations, predictions using parameters recovered from recombinant enzymes will provide more conservative estimates of interaction liability.

The large milk thistle doses required to achieve a relatively low risk of interaction with midazolam suggest that the clinical interaction liability of milk thistle may be limited to substrates sensitive to extensive intestinal first-pass extraction (e.g., simvastatin, felodipine) and/or to patient populations at risk for elevated milk thistle exposure (e.g., impaired hepatic function). Self-administration of milk thistle

### Table 3

Inactivation kinetics of selected milk thistle constituents and extract

<table>
<thead>
<tr>
<th>Constituent/Extract</th>
<th>K$_{h}$</th>
<th>$k_{inact}$</th>
<th>$k_{inact}/K_{h}$</th>
<th>t$_{1/2}$</th>
<th>K$_{max}$</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>μM</td>
<td>min$^{-1}$</td>
<td>μl/min/pmol min</td>
<td>min</td>
<td>min$^{-1}$</td>
</tr>
<tr>
<td>Silybin A</td>
<td>100 ± 27</td>
<td>0.22 ± 0.02</td>
<td>2.2</td>
<td>3.2</td>
<td>0.025 ± 0.005</td>
</tr>
<tr>
<td>Silybin B</td>
<td>89 ± 60</td>
<td>0.15 ± 0.04</td>
<td>1.7</td>
<td>4.5</td>
<td>0.023 ± 0.008</td>
</tr>
<tr>
<td>Silibinin</td>
<td>110 ± 15</td>
<td>0.20 ± 0.01</td>
<td>1.8</td>
<td>3.5</td>
<td>0.016 ± 0.002</td>
</tr>
</tbody>
</table>

$t_{1/2}$, half-life.
products is particularly popular among hepatitis C patients, in which an estimated 33% have used milk thistle as part of their therapeutic regimen (Seeff et al., 2008). Compared with healthy volunteers, patients with impaired hepatic function, including those with hepatitis C, demonstrated increased plasma exposure to milk thistle flavonolignans (Schrieber et al., 2008). Whereas the disease-related decrease in hepatic function alone could place these patients at increased risk for metabolic drug-drug interactions, intake of milk thistle products may provide an additional insult, increasing the risk for adverse events.

In summary, herb-drug interaction predictions are challenging due to the multitude of bioactive constituents typically composing herbal products. As such, identification of individual perpetrator compound(s) is necessitated. The current work outlines a framework to facilitate prospective evaluation of herb-drug interaction potential using milk thistle as a model herbal product. Of the eight constituents tested, this approach identified two constituents, silybin A and silybin B, which may-perpetrate interactions via MBI of intestinal CYP3A activity. Products enriched with these constituents, such as silybin, may have increased herb-drug interaction liability compared with other milk thistle products. Intestinal concentrations of these constituents could achieve those near the \( K_I \) (~100 \( \mu \)M), particularly with gram doses of silybin that have been tested in patient populations (Flaig et al., 2007). Modeling and simulation incorporating these higher doses would help assess interaction liability of milk thistle products with CYP3A substrates sensitive to first-pass elimination. Refinement and application of this framework to other herbal products ultimately may assist clinicians and consumers to make informed decisions about the consequences of adding an herbal product to conventional pharmacotherapeutic regimens.

Acknowledgments

The authors thank Dr. Dhiren Thakker for his insightful discussions during the planning of experiments. M.F.P. dedicates this article to Dr. David P. Paine.

Authorship Contributions

Participated in research design: Brantley, Graf, Oberlies, Paine.

Conducted experiments: Brantley, Graf.

Contributed new reagents or analytic tools: Graf, Oberlies.

Performed data analysis: Brantley, Graf, Oberlies, Paine.

Wrote or contributed to the writing of the manuscript: Brantley, Graf, Oberlies, Paine.

References


Address correspondence to: Dr. Mary F. Paine, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, 2320 Kerr Hall, CB #7569, Chapel Hill, NC 27599-7569. E-mail: mpaine@unc.edu